Portal de investigação
COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Miranda, J
- Amaral, L
- Castro, E
- Coimbra, A
- Placido, JL
Unidades de investigação
Abstract
Reported cases of anaphylaxis following COVID-19 vaccination raised concerns about the safety of these vaccines, namely in patients suffering from clonal mast cell (MC) disorders-a heterogenous group of disorders in which patients may be prone to anaphylaxis caused by vaccination. This study aimed to assess the safety of COVID-19 vaccines in patients with clonal MC disorders. We performed an ambidirectional cohort study with 30 clonal MC disorder patients (n = 26 in the prospective arm and n = 4 in the retrospective arm), that were submitted to COVID-19 vaccination. Among these, 11 (37%) were males, and median age at vaccination date was 41 years (range: 5y to 76y). One patient had prior history of anaphylaxis following vaccination. Those in the prospective arm received a premedication protocol including H1- and H2-antihistamines and montelukast, while those in the retrospective arm did not premedicate. Overall, patients received a total of 81 doses, 73 under premedication and 8 without premedication. No MC activation symptoms were reported. COVID-19 vaccination seems to be safe in patients with clonal mast cell disorders, including those with prior anaphylaxis following vaccination. Robust premedication protocols may allow for vaccination in ambulatory settings.
Dados da publicação
- ISSN/ISSNe:
- 2076-393X, 2076-393X
- Tipo:
- Article
- Páginas:
- 718-
- Link para outro recurso:
- www.scopus.com
Vaccines Multidisciplinary Digital Publishing Institute (MDPI)
Citações Recebidas na Web of Science: 6
Citações Recebidas na Scopus: 9
Documentos
- Não há documentos
Filiações
Keywords
- COVID-19 vaccines; mastocytosis; clonal mast cell activation syndrome; anaphylaxis
Financiamento
Proyectos asociados
Airborne food and aeroallergens levels in healthcare settings. An unaccounted but potentially relevant source of exposure?
Investigador Principal: André Miguel Afonso de Sousa Moreira
Estudo Clínico Académico (Aeroallergens) . 2020
Eosinophil cationic protein (ECP) correlates with eosinophil cell counts in the induced sputum of elite swimmers
Investigador Principal: André Miguel Afonso de Sousa Moreira
Estudo Clínico Académico (ECP) . 2021
How exercise, physical activity and diet modulate immune and stress responses
Investigador Principal: André Miguel Afonso de Sousa Moreira
Estudo Clínico Académico . 2020
Citar a publicação
Rama T,Miranda J,Silva D,Amaral L,Castro E,Coimbra A,Moreira A,Placido JL. COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication. Vaccines. 2022. 10. (5):p. 718-718. IF:7,800. (1).
